Jennison Associates
IMVT icon

Jennison Associates’s Immunovant IMVT Stock Holding History

Jennison Associates’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$128M Buy
3,310,238
+113,533
+4% +$3.46M 0.08% 125
2026
Q1 		$79.4M Buy
3,196,705
+2,496,241
+356% +$64.6M 0.05% 163
2025
Q4 		$17.8M Buy
+700,464
New +$15.6M 0.01% 352
2024
Q1 		– Sell
-313,205
Closed -$13.2M – 610
2023
Q4 		$13.2M Buy
313,205
+14
+0% +$515 0.01% 362
2023
Q3 		$12M Buy
+313,191
New +$7.08M 0.01% 358

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jennison Associates's IMVT Position: Q2 2026 in Review

Jennison Associates increased its Immunovant (IMVT) stake by 3.6% in Q2 2026, buying an estimated $3.46M and bringing the position to 3,310,238 shares worth $128M. The position accounts for 0.08% of the portfolio, ranked #125.

Jennison Associates first reported a position in IMVT in Q3 2023 and has held it in 5 quarters since. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Jennison Associates held 3,310,238 shares of Immunovant worth $128M as of Q2 2026.
  • Jennison Associates bought 113,533 Immunovant shares in Q2 2026, an estimated $3.46M.
  • Immunovant made up 0.08% of Jennison Associates's portfolio in Q2 2026, its #125 holding.
  • Jennison Associates first reported a position in Immunovant in Q3 2023 and has held it in 5 quarters since.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Jennison Associates's 13F filing for Q2 2026, filed 3 Aug 2026.